Evidence map›Paper›PMID 31953482›Full record

Trial reportSpinal cord2020

Effect of probiotics on multi-resistant organism colonisation in persons with spinal cord injury: secondary outcome of ProSCIUTTU, a randomised placebo-controlled trial.

Swee-Ling Toh, Bonsan Bonne Lee, Judy M Simpson, Scott A Rice, George Kotsiou, Obaydullah Marial, Suzanne Ryan

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Spinal cord, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Microorganisms · 2023
    Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Swee-Ling TohDepartment of Spinal and Rehabilitation Medicine, Prince of Wales Hospital, Sydney, NSW, Australia. SweeLing.Toh@health.nsw.gov.au.
Bonsan Bonne LeeDepartment of Spinal and Rehabilitation Medicine, Prince of Wales Hospital, Sydney, NSW, Australia.
Judy M SimpsonSydney School of Public Health, University of Sydney, Sydney, NSW, Australia.
Scott A RiceSingapore Centre for Environmental Life Sciences Engineering and the School of Biological Sciences, Nanyang Technological University, Nanyang, Singapore.ORCID http://orcid.org/0000-0002-9486-2343
George KotsiouDepartment of Infectious Diseases and Microbiology, NSW Health Pathology, Royal North Shore Hospital, Sydney, NSW, Australia.
Obaydullah MarialNeuroscience Research Australia (NeuRA) and UNSW Sydney, Sydney, NSW, Australia.
Suzanne RyanNeuroscience Research Australia (NeuRA) and UNSW Sydney, Sydney, NSW, Australia.
UNSW Sydney · AUThe University of Sydney · AURoyal North Shore Hospital · AUUniversity of Technology Sydney · AU

Funding

Department of Health | National Health and Medical Research Council (NHMRC) 630448
6 · The paper itself

Abstract

STUDY

designRandomised double-blind placebo-controlled trial.

objectivesMulti-resistant organism (MRO) colonisation is common in people with SCI. We aimed to determine whether Lactobacillus reuteri RC-14 + Lactobacillus GR-1 (RC14-GR1) and/or Lactobacillus rhamnosus GG + Bifidobacterium BB-12 (LGG-BB12) are effective in preventing or clearing MRO colonisation.

settingNew South Wales, Australia.

methodsThe 207 SCI participants were randomised to one of four arms: (i) RC14-GR1 + LGG-BB12, (ii) RC14-GR1 + placebo, (iii) LGG-BB12 + placebo or (iv) double placebos for 6 months. Microbiological samples of nose, groin, urine and bowel were taken at baseline, 3 and 6 months. Analysis was conducted for the presence of methicillin-resistant Staphylococcus aureus (MRSA), multi-resistant gram-negative organisms (MRGNs) and vancomycin-resistant enterococcus (VRE). The outcomes were clearance of, or new colonisation with MRSA, MRGN, VRE or MROs and whether participants remained free of MRSA, MRGN, VRE or MROs throughout the study. Risk factors associated with an outcome were adjusted for using nominal or binary logistic regression.

resultsThere was a significant reduction in new MRGN colonisation compared with placebo for participants treated with RC14-GR1 (OR 0.10, 95% CI, 0.01-0.88, P = 0.04), after allowing that inpatients were more likely to be newly colonised (OR 21.41, 95% CI, 3.98-115.13, P < 0.0001). Participants who intermittent self-catheterised (IMC) were more likely to remain MRO-free than those utilising SPC or IDCs (OR 2.80, 95% CI, 1.41-5.54, P = 0.009).

conclusionsProbiotics are ineffective at clearing MROs in people with SCI. However, RC14-GR1 is effective at preventing new colonisation with MRGNs. The use of IMC significantly improves the chance of remaining MRO-free.

Indexed as

BifidobacteriumDrug Resistance, Multiple, BacterialLacticaseibacillus rhamnosusLimosilactobacillus reuteriMethicillin ResistanceMicrobiotaVancomycin ResistanceAdultDouble-Blind MethodFemaleHumansMaleMiddle AgedNew South WalesOutcome Assessment, Health CareProbiotics

Identifiers

PMID31953482
OpenAlexW3000217863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.